What counted as worsening mental illness?
The researchers used Swedish health registers from 2009 through 2022, and the cohort was 59.7% female with a mean age of 50.6 years. It counted four outcomes together: psychiatric hospitalization, more than 14 days of psychiatric sick leave, hospitalization for self-harm, and death by suicide [1]. These records capture serious events and extended work absences. Changes in day-to-day symptoms may occur without any of those events.
The main comparison used periods with each medicine and periods without GLP-1 receptor agonist use in the same person, which helps account for characteristics that stay constant. The semaglutide dose study asked a different question by comparing recorded diagnoses among people who reached different doses. These estimates do not establish whether one drug is better than another for mental health.
What the estimates showed
For the main combined outcome, semaglutide had an adjusted hazard ratio of 0.58 (95% CI 0.51–0.65) and liraglutide 0.82 (0.76–0.89). The estimates were 1.01 (0.69–1.46) for exenatide and 1.01 (0.85–1.20) for dulaglutide. Both of those intervals include 1 and leave room for either lower or higher risk.
Secondary analyses found that periods of semaglutide use were associated with lower risk of worsening depression (0.56, 0.44–0.71), anxiety (0.62, 0.52–0.73), and substance use disorder (0.53, 0.35–0.80). For liraglutide, the detectable association among those three outcomes was for worsening depression (0.74, 0.64–0.87). GLP-1 receptor agonist use as a group was associated with lower risk in a separate analysis of self-harm (0.56, 0.34–0.92) [1].
What this study leaves open
Changes over time in other medications, clinical care or symptom severity may still influence the associations. A separate South Korean hospital cohort found more new depression and anxiety diagnoses among Wegovy initiators than among matched non-initiators. It measured different outcomes in a different population. Neither observational study establishes that semaglutide caused the difference in diagnoses or that it treats an existing psychiatric condition [2].
The Sigrid Jusélius Foundation, Jane and Aatos Erkko Foundation, and Finnish Ministry of Social Affairs and Health funded the Swedish study. Several authors disclosed relationships with pharmaceutical companies [1].
For someone taking an antipsychotic, studies on GLP-1 medicines for antipsychotic-related weight gain address a separate treatment question about managing weight gain during care.
The evidence on suicidal thoughts and behavior includes separate FDA and EMA reviews of suicidality and related events. The FDA requested removal of the suicidal behavior and ideation warning from Wegovy, Saxenda and Zepbound labeling after finding no increased risk in its review [3]. The EMA review of several GLP-1 medicines also found no evidence supporting a causal link with suicidal or self-injurious thoughts and actions [4]. Those reviews address specific safety concerns and do not establish a mental-health treatment effect.
Discuss medication choices and changes in mental health with the clinicians involved in both areas of care.